Knelson, Erik H.

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell

Hippo pathway signaling and YAP/TAZLung Cancer Treatments and Mutations

Cited by 475

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., et al. (2021) · Cancer Discovery

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 227

STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

Berger, G., Knelson, E. H., Jimenez-Macias, J. L., Nowicki, M. O., Han, S., Panagioti, E., Lizotte, P. H., Adu-Berchie, K., Stafford, A., Dimitrakakis, N., et al. (2022) · Proceedings of the National Academy of Sciences

interferon and immune responsesGlioma Diagnosis and Treatment

Cited by 179

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 107

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Knelson, E. H., Ivanova, E. V., Tarannum, M., Campisi, M., Lizotte, P. H., Booker, M. A., Ozgenc, I., Noureddine, M., Meisenheimer, B., Chen, M., et al. (2022) · Cancer Immunology Research

interferon and immune responsesImmune Cell Function and Interaction

Cited by 88

A bright future for KRAS inhibitors

Bar-Sagi, D., Knelson, E. H., & Sequist, L. V. (2020) · Nature Cancer

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 74